360° SearchNetwork Hot Spots Trends Time Series

Exubera

Type: Product

Name: Exubera

First reported 11 hours ago - Updated 11 hours ago - 1 reports

MannKind's Run to Glory

What's caused this increase?Increased revenue? Nope, MannKind doesn't have any products for sale.Clinical trial data? Not really. The company completed enrollment for two phase 3 trials testing its inhaled insulin Afrezza in October, but the trials aren't ... [Published Motley Fool - 11 hours ago]

Entities: MannKind Corp, Insulin, Exubera

First reported 16 hours ago - Updated 16 hours ago - 1 reports

MannKind Corp

Sentiment Drives MannKind to Fresh Highs Ahead of Vital Catalyst

An enormous amount of hype in the last couple of weeks has sent the diabetes and cancer drug developer MannKind Corporation (NASDAQ: MNKD) soaring, particularly after the company’s first quarter financial results for fiscal year 2013 on May 9th.After ... [Published BioMedReports - 16 hours ago]

Entities: MannKind Corp, Phase III, Catalyst

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Pricing A Highly Probable Takeover Of MannKind

Investors, or more accurately, speculators who have followed the MannKind Corporation (NASDAQ: MNKD) saga over the past several years know full well that the end game is rapidly approaching. Wall Street research coverage has increased of late, trading ... [Published Seeking Alpha - May 22 2013]

Entities: MannKind Corp, Insulin, FDA Food & Drug Administration, Diabetes, Exubera

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Failed insulin drug technology may play key role in stemming maternal mortality

Michelle McIntosh, lead researcher of Monash Institute of Pharmaceutical Sciences, says her group plans to start testing a dry-powdered form of oxytocin by early 2014. Source: Monash University via Bloomberg A hormone treatment based on technology used ... [Published Irish Times - May 21 2013]

Entities: Oxytocin, Insulin, Exubera

First reported May 19 2013 - Updated May 20 2013 - 3 reports

Pfizer Inc

Can Pfizer’s Love Hormone Cut Down Maternal Mortality?

Oxytocin is a brain chemical that helps the uterus contract after birth and is occasionally referred to as the “love hormone” because of its role in couples’ bonding. Used preventatively, it can actually cut the rate of post-delivery bleeding complications ... [Published Wall St. Cheat Sheet - May 20 2013]

Entities: Pfizer Inc, Oxytocin, Hormone

First reported May 19 2013 - Updated May 20 2013 - 1 reports

FDA Food & Drug Administration

Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin

A hallmark disease of an overweight, desk bound nation, diabetes instigates a staggering economic burden on our healthcare system where total costs, including hospital inpatient care, doctor visits, medication, and reduced or lost productivity have been ... [Published Seeking Alpha - May 19 2013]

Entities: Insulin, Diabetes, FDA Food & Drug Administration, Drugs

First reported May 18 2013 - Updated May 18 2013 - 2 reports

Why MannKind's Afrezza Will Succeed Where Pfizer Failed

Home » Blogs » According to the American Diabetes Association over 25 million people in the US alone have diabetes and the numbers keep on growing. Although insulin injections have come a long way, poking yourself with a needle in public still draws unwanted ... [Published BioPortfolio - May 18 2013]

Entities: MannKind Corp, Pfizer Inc, Insulin, Exubera, Inhalation

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Drug Delivery: Packaging Drug Delivery

PULMONARY ROUTEIn March 2005, Pfizer Inc. (New York City) and the Sanofi-Aventis Group (Paris) announced that FDA had accepted their new drug application for Exubera, a dry-powder form of insulin inhaled into the lungs. Nektar (San Carlos, CA) manufactures ... [Published Pharmaceutical & Medical Packaging News - May 13 2013]

Entities: Becton Dickinson and Company, Drug Delivery, Drugs, OptiNose, Polymer

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Responding To Adam Feuerstein On Afrezza

The Street's Adam Feuerstein's latest attack on MannKind (MNKD) makes several "scary"claims:We should be scared because MannKind is running a study to clear Afrezza for use on people with Mild Obstructive Pulmonary Disease A 2008 study had a high drop-out ... [Published Seeking Alpha - Apr 17 2013]

Entities: Exubera, Insulin, Pulmonary Disease

Quotes

...It also may be instructive to note that during a , Mr. Mann stated "I believe AFREZZA could potentially even become the most significant medical product ever." It would be easy to dismiss this statement as hyperbole or the wishful musings of a corporate chieftain, but the speaker's extraordinary life story...

Pricing A Highly Probable Takeover Of MannKind [Published Seeking Alpha - May 22 2013]

"Exubera was the first generation," said John Patton, one of the original inventors of Pfizer’s inhaled insulin technology system. "When you’re first, you take a lot of bullets."

Failed insulin drug technology may play key role in stemming maternal mortality [Published Irish Times - May 21 2013]

1) Afrezza could be cleared for people with Mild Obstructive Pulmonary Disease, good! The current studies are for people who do not have "History of COPD, asthma, or any other clinically important pulmonary disease" this could open Afrezza up to these people

Responding To Adam Feuerstein On Afrezza [Published Seeking Alpha - Apr 17 2013]

More Content

sort by: Date \| Relevance
MannKind's Run to Glory [Published Motley Fool - 11 hours ago]
MannKind Corporation (MNKD), PDL BioPharma Inc.... [Published InsiderMonkey.com - 14 hours ago]
MannKind's Afrezza And The Oramed Threat [Published BioPortfolio - 16 hours ago]
Sentiment Drives MannKind to Fresh Highs Ahead ... [Published BioMedReports - 16 hours ago]
MannKind's Afrezza And The Oramed Threat [Published Seeking Alpha - 18 hours ago]
Pricing A Highly Probable Takeover Of MannKind [Published Seeking Alpha - May 22 2013]
Failed insulin drug technology may play key rol... [Published Irish Times - May 21 2013]
Can Pfizer’s Love Hormone Cut Down Maternal Mor... [Published Wall St. Cheat Sheet - May 20 2013]
Can Pfizer’s Love Hormone Cut Down Maternal Mor... [Published Wall St. Cheat Sheet - May 20 2013]
‘Love Hormone’ Drug Promises Safer Births Follo... [Published Bloomberg - May 19 2013]
Oramed Sweeps Past Worldwide Giants With The Fi... [Published Seeking Alpha - May 19 2013]
Why MannKind's Afrezza Will Succeed Where Pfize... [Published BioPortfolio - May 18 2013]
Why MannKind's Afrezza Will Succeed Where Pfize... [Published Seeking Alpha - May 18 2013]
Drug Delivery: Packaging Drug Delivery [Published Pharmaceutical & Medical Packaging News - May 13 2013]
MannKind's Countdown to Liftoff? [Published Motley Fool Discussion Boards - May 10 2013]
Responding To Adam Feuerstein On Afrezza [Published Seeking Alpha - Apr 17 2013]
Method of controlling glycemia by ultrarapid ac... [Published PharmCast - Sep 21 2012]
Fact Sheet for Pfizer Inc. [Published Able2Act - Jan 08 2008]

Blogs

sort by: Date \| Relevance
Can Pfizer’s Love Hormone Cut Down Maternal Mor... [Published Wall St. Cheat Sheet - May 20 2013] Oxytocin is a brain chemical that helps the uterus contract after birth and is occasionally referred to as the “love hormone” because of its role in couples’ bonding. Used preventatively, it can actually cut the rate of post-delivery bleeding complications ...
Can Pfizer’s Love Hormone Cut Down Maternal Mor... [Published Wall St. Cheat Sheet - May 20 2013] Oxytocin is a brain chemical that helps the uterus contract after birth and is occasionally referred to as the “love hormone” because of its role in couples’ bonding. Used preventatively, it can actually cut the rate of post-delivery bleeding complications ...